| Literature DB >> 28040716 |
Mary B Daly1, Robert Pilarski2, Michael Berry3, Saundra S Buys4, Meagan Farmer5, Susan Friedman6, Judy E Garber7, Noah D Kauff8, Seema Khan9, Catherine Klein10, Wendy Kohlmann4, Allison Kurian11, Jennifer K Litton12, Lisa Madlensky13, Sofia D Merajver14, Kenneth Offit15, Tuya Pal16, Gwen Reiser17, Kristen Mahoney Shannon18, Elizabeth Swisher19, Shaveta Vinayak20, Nicoleta C Voian21, Jeffrey N Weitzel22, Myra J Wick23, Georgia L Wiesner24, Mary Dwyer25, Susan Darlow25.
Abstract
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.Entities:
Mesh：
Year: 2017 PMID： 28040716 DOI： 10.6004/jnccn.2017.0003
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908